Stockscreener 앱 받기
63.15
1.33%
0.8454
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech - Yahoo Finance
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Increased by Federated Hermes Inc. - MarketBeat
Stories on US FDA approving injectable Roche multiple sclerosis therapy are withdrawn - Reuters
H.C. Wainwright maintains Halozyme stock at Buy after early Tecentriq approval - Investing.com Canada
Roche wins FDA nod for Tecentriq version developed with Halozyme - MSN
HALOHalozyme Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis - Citizentribune
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis - StockTitan
Halozyme CEO sells over $1.7m in company stock By Investing.com - Investing.com Australia
Halozyme Therapeutics (NASDAQ:HALO) Receives "Buy" Rating from HC Wainwright - MarketBeat
Critical Insights From Halozyme Therapeutics Analyst Ratings: What You Need To Know - Benzinga
H.C. Wainwright maintains Halozyme stock at Buy after early Tecentriq approval - Investing.com UK
Roche wins FDA nod for Halozyme Tecentriq version (OTCQX:RHHBY) - Seeking Alpha
Halozyme Therapeutics Says FDA Approves Tecentriq Hybreza Cancer Immunotherapy - Marketscreener.com
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer - Citizentribune
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer - StockTitan
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer - PR Newswire
Halozyme CEO sells over $1.7m in company stock By Investing.com - Investing.com Canada
Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Sells 10,000 Shares of Stock - MarketBeat
Halozyme CEO sells over $1.7m in company stock - Investing.com
Halozyme CEO sells over $1.7m in company stock By Investing.com - Investing.com UK
Doheny Asset Management CA Takes $6.47 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Analysts Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) Target Price at $59.44 - MarketBeat
Natixis Advisors LLC Grows Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
TD Asset Management Inc Sells 175,283 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Kornitzer Capital Management Inc. KS Purchases 37,500 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Pertuzumab Market Share Growth Status, Emerging Technology, - openPR
Halozyme Therapeutics And 4 Other Stocks Have High Sales Growth And An Above 3% Return on Equity - Via News Agency
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Hodges Capital Management Inc. - MarketBeat
How To Trade (HALO) - Stock Traders Daily
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Short Interest Up 8.0% in August - MarketBeat
Pertuzumab Market Overview, Analysis, Futuristic Trend, - openPR
Hussman Strategic Advisors Inc. Has $2.20 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Mizuho Markets Americas LLC Reduces Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Why Halozyme Shares Plunged - Yahoo Movies Canada
Zacks Research Analysts Raise Earnings Estimates for Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme stock soars to all-time high of $65.13 By Investing.com - Investing.com Australia
Raymond James Trust N.A. Takes $246,000 Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme stock soars to all-time high of $65.13 By Investing.com - Investing.com Canada
Halozyme stock soars to all-time high of $65.13 - Investing.com
Halozyme stock soars to all-time high of $65.13 By Investing.com - Investing.com UK
Raymond James Trust N.A. Acquires Shares of 4,689 Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
Legato Capital Management LLC Makes New $765,000 Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme to Present at Upcoming Investor Conferences - StockTitan
SVP, CHIEF TECHNICAL OFFICER Labarre Michael J. exercised 5,580 shares at a strike of $18.41, increasing direct ownership by 3% to 173,756 units (SEC Form 4) - Quantisnow
Allspring Global Investments Holdings LLC Lowers Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Top 2 Health Care Stocks That May Plunge In August - Benzinga
SG Americas Securities LLC Lowers Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2028 - Marketscreener.com
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Increased by Retirement Systems of Alabama - MarketBeat
AMI Asset Management Corp Reduces Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Earnings, Guidance Point to Bullish Future - Yahoo Finance
Halozyme Earnings, Guidance Point to Bullish Future - FX Empire
Fifth Third Wealth Advisors LLC Invests $225,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
1.26%
1.71%
자본화:
|
볼륨(24시간):